News | July 08, 2025
Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day
The company showcased three core programs developed through this platform
The company showcased three core programs developed through this platform
Extended lab space for product development, customer demos, and training
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Reaffirms Lupin’s commitment to sustainable resource management
Dr. Muthu was last associated with Mankind Pharma
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Subscribe To Our Newsletter & Stay Updated
